• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Thorne Healthtech Inc.

    10/16/23 9:44:51 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRN alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40826
    Issuer: Thorne Healthtech, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 152 W. 57th Street
    New York NEW YORK 10019
    Telephone number: 917-859-2505
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-10-16 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $THRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THRN

    DatePrice TargetRatingAnalyst
    11/17/2022$5.50Buy
    Canaccord Genuity
    10/18/2021$11.00Buy
    B of A Securities
    10/18/2021Buy
    BofA Securities
    10/18/2021$13.00Outperform
    Evercore ISI Group
    10/18/2021$11.00Outperform
    Cowen & Co.
    10/18/2021$11.00Outperform
    RBC Capital
    More analyst ratings

    $THRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Thorne HealthTech with a new price target

    Canaccord Genuity initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $5.50

    11/17/22 7:24:31 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B of A Securities initiated coverage on Thorne HealthTech with a new price target

    B of A Securities initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $11.00

    10/18/21 10:22:55 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Thorne HealthTech

    BofA Securities initiated coverage of Thorne HealthTech with a rating of Buy

    10/18/21 9:20:07 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Varma Saloni S. returned 581,643 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 5:01:44 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mckenna Thomas P. returned 1,172,227 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 5:00:39 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mccamy William C. returned 589,804 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 4:59:36 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    SEC Filings

    View All

    SEC Form 15-12G filed by Thorne Healthtech Inc.

    15-12G - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/26/23 6:03:57 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Thorne Healthtech Inc.

    S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/16/23 4:54:57 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Thorne Healthtech Inc.

    S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/16/23 4:53:59 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    L Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender Offer

    NEW YORK, Oct. 13, 2023 /PRNewswire/ -- L Catterton and Thorne HealthTech, Inc. ("Thorne") (NASDAQ:THRN) today announced that the tender offer to purchase all of the issued and outstanding shares of Thorne's common stock ("Shares") for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended (such date and time, the "Expiration Time"). Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised L Catterton that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly

    10/13/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifshitz Law PLLC Announces Investigations of ABCM, THRN, BHRB, and AGE

    NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Abcam Plc (NASDAQ:ABCM) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ABCM to Danaher Corporation for $24.00 per share in cash for each share of ABCM common stock owned. If you are an ABCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Thorne HealthTech, Inc. (NASDAQ:THRN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TRHN to L Catter

    9/2/23 7:47:00 PM ET
    $ABCM
    $BHRB
    $THRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Banks
    Finance

    Thorne HealthTech, Inc. Enters into Definitive Agreement to be Acquired by L Catterton for $10.20 Per Share in Cash

    L Catterton to Commence a Tender Offer for all of Thorne's Outstanding Shares of Common Stock Thorne Stockholders to Receive $10.20 per Share in Cash, Representing a 94% Premium to the Unaffected Price Independent Special Committee and Thorne Board of Directors Unanimously Approve Transaction and Recommend that All Stockholders Tender Their Shares in the Tender Offer  NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused inv

    8/28/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Leadership Updates

    Live Leadership Updates

    View All

    Thorne HealthTech Appoints Saloni Varma as New Chief Financial Officer

    NEW YORK, March 13, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ:THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has appointed Saloni Varma as Chief Financial Officer (CFO). As CFO, Varma will lead all aspects of the company's Accounting and Finance functions including budgeting planning and analysis, accounting, SEC reporting, tax, treasury, and investor relations. Varma brings more than 20 years of experience across a range of consumer goods companies, mos

    3/13/23 7:30:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Financials

    Live finance-specific insights

    View All

    Thorne HealthTech Reports Second Quarter 2023 Results

    Record Net Sales With Growth of 33.1%; Raises Full-Year Guidance Midpoints for Net Sales and Gross Margin NEW YORK, Aug. 8, 2023  /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter Highlights: Net sales grew 33.1% year-over-year to $72.7 million, with direct-to-consumer ("DTC") sales growth of 39.3%Gross profit grew 35.7% year-over-year to $40.6 million; gross profit as a % of net sales increased year-over-year to 55.9%.Net incom

    8/8/23 4:05:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thorne HealthTech Schedules Second Quarter 2023 Earnings Release and Conference Call for August 8

    Company Withdraws Participation in the Canaccord Genuity 43rd Annual Growth Conference on Aug. 10 NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its second quarter 2023 financial results after market close on Tuesday, Aug. 8, 2023. The company will host a conference call to discuss its results on Tuesday, Aug. 8, 2023, at 5:00 p.m. (U.S. Eastern Time). A live webcast and replay of the call will be available on the investors section of the

    8/1/23 5:15:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thorne HealthTech Reports First Quarter 2023 Results

    Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK, May 11, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Highlights: Net sales grew 20.7% year-over-year to $65.2 million, with direct-to-consumer ("DTC") sales growth of 41.0%Gross profit grew 16.3% year-over-year to $34.3 million; gross p

    5/11/23 4:05:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    11/6/23 3:57:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    10/17/23 4:10:56 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    2/10/23 5:04:59 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care